Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Tsai, TH
   Analytical approaches for traditional Chinese medicines exhibiting antineoplastic activity
   JOURNAL OF CHROMATOGRAPHY B
   
   T.H. Tsai, "Analytical approaches for traditional Chinese medicines exhibiting antineoplastic activity", J CHROMAT B, 764(1-2), 2001, pp. 27-48
2. Oguma, T
   Antitumor drugs possessing topoisomerase I inhibition: applicable separation methods
   JOURNAL OF CHROMATOGRAPHY B
   
   T. Oguma, "Antitumor drugs possessing topoisomerase I inhibition: applicable separation methods", J CHROMAT B, 764(1-2), 2001, pp. 49-58
3. Palumbo, M; Sissi, C; Gatto, B; Moro, S; Zagotto, G
   Quantitation of camptothecin and related compounds
   JOURNAL OF CHROMATOGRAPHY B
   
   M. Palumbo et al., "Quantitation of camptothecin and related compounds", J CHROMAT B, 764(1-2), 2001, pp. 121-140
4. Zufia, L; Aldaz, A; Giraldez, J
   Separation methods for camptothecin and related compounds
   JOURNAL OF CHROMATOGRAPHY B
   
   L. Zufia et al., "Separation methods for camptothecin and related compounds", J CHROMAT B, 764(1-2), 2001, pp. 141-159
5. Jung, LL; Zamboni, WC
   Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
   DRUG RESISTANCE UPDATES
   
   L.L. Jung e W.C. Zamboni, "Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?", DRUG RESIST, 4(3), 2001, pp. 152-167
6. Mathijssen, RHJ; van Alphen, RJ; Verweij, J; Loos, WJ; Nooter, K; Stoter, G; Sparreboom, A
   Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
   CLINICAL CANCER RESEARCH
   
   R.H.J. Mathijssen et al., "Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)", CLIN CANC R, 7(8), 2001, pp. 2182-2194
7. Takimoto, CH
   Why drugs fail: Of mice and men revisited
   CLINICAL CANCER RESEARCH
   
   C.H. Takimoto, "Why drugs fail: Of mice and men revisited", CLIN CANC R, 7(2), 2001, pp. 229-230
8. Kirstein, MN; Houghton, PJ; Cheshire, PJ; Richmond, LB; Smith, AK; Hanna, SK; Stewart, CF
   Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts
   CLINICAL CANCER RESEARCH
   
   M.N. Kirstein et al., "Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts", CLIN CANC R, 7(2), 2001, pp. 358-366
9. Minami, H; Fujii, H; Igarashi, T; Itoh, K; Tamanoi, K; Oguma, T; Sasaki, Y
   Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks
   CLINICAL CANCER RESEARCH
   
   H. Minami et al., "Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks", CLIN CANC R, 7(10), 2001, pp. 3056-3064
10. Senter, PD; Beam, KS; Mixan, B; Wahl, AF
    Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug
    BIOCONJUGATE CHEMISTRY
    
    P.D. Senter et al., "Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug", BIOCONJ CHE, 12(6), 2001, pp. 1074-1080
11. Takagi, T; Saotome, T
    Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma
    LEUKEMIA & LYMPHOMA
    
    T. Takagi e T. Saotome, "Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma", LEUK LYMPH, 42(4), 2001, pp. 577-586
12. Launois, R; Portafax, C; Le Lay, K; Megnigbeto, A; Perrocheau, G
    Internet pharmaco-economic studies in metastatic colorectal cancer
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    
    R. Launois et al., "Internet pharmaco-economic studies in metastatic colorectal cancer", CR R ONC H, 38(1), 2001, pp. 63-77
13. Platzer, P; Thalhammer, T; Reznicek, G; Hamilton, G; Zhang, RW; Jager, W
    Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver
    INTERNATIONAL JOURNAL OF ONCOLOGY
    
    P. Platzer et al., "Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver", INT J ONCOL, 19(6), 2001, pp. 1287-1293
14. Maindrault-Goebel, F; de Gramont, A; Louvet, C; Andre, T; Carola, E; Mabro, M; Artru, P; Gilles, V; Lotz, JP; Izrael, V; Krulik, M
    High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)
    EUROPEAN JOURNAL OF CANCER
    
    F. Maindrault-Goebel et al., "High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)", EUR J CANC, 37(8), 2001, pp. 1000-1005
15. Cunningham, D; James, RD
    Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer
    EUROPEAN JOURNAL OF CANCER
    
    D. Cunningham e R.D. James, "Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer", EUR J CANC, 37(7), 2001, pp. 826-834
16. Alonso, V; Escudero, P; Zorrilla, M; Isla, MD; Herrero, A; Mayordomo, JI; Martinez-Trufero, J; Saenz, A; Tres, A; Anton, A
    Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer
    EUROPEAN JOURNAL OF CANCER
    
    V. Alonso et al., "Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer", EUR J CANC, 37(18), 2001, pp. 2385-2391
17. Ohe, Y; Yamamoto, S; Suzuki, K; Hojo, F; Kakinuma, R; Matsumoto, T; Ohmatsu, H; Nishiwaki, Y
    Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer
    EUROPEAN JOURNAL OF CANCER
    
    Y. Ohe et al., "Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer", EUR J CANC, 37(1), 2001, pp. 54-63
18. Guichard, S; Arnould, S; Hennebelle, I; Bugat, R; Canal, P
    Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo
    ANTI-CANCER DRUGS
    
    S. Guichard et al., "Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo", ANTI-CANC D, 12(9), 2001, pp. 741-751
19. Ong, SYK; Clarke, SJ; Bishop, J; Dodds, HM; Rivory, LP
    Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction
    ANTI-CANCER DRUGS
    
    S.Y.K. Ong et al., "Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction", ANTI-CANC D, 12(7), 2001, pp. 619-625
20. Yamamoto, W; Verweij, J; de Bruijn, P; de Jonge, MJA; Takano, H; Nishiyama, M; Kurihara, M; Sparreboom, A
    Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells
    ANTI-CANCER DRUGS
    
    W. Yamamoto et al., "Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells", ANTI-CANC D, 12(5), 2001, pp. 419-432
21. Kehrer, DFS; Soepenberg, O; Loos, WJ; Verweij, J; Sparreboom, A
    Modulation of camptothecin analogs in the treatment of cancer: a review
    ANTI-CANCER DRUGS
    
    D.F.S. Kehrer et al., "Modulation of camptothecin analogs in the treatment of cancer: a review", ANTI-CANC D, 12(2), 2001, pp. 89-105
22. Demarquay, D; Huchet, M; Coulomb, H; Lesueur-Ginot, L; Lavergne, O; Kasprzyk, PG; Bailly, C; Camara, J; Bigg, DCH
    The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison
    ANTI-CANCER DRUGS
    
    D. Demarquay et al., "The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison", ANTI-CANC D, 12(1), 2001, pp. 9-19
23. Green, MR
    The current status of docetaxel for advanced non-small cell lung cancer
    ANTI-CANCER DRUGS
    
    M.R. Green, "The current status of docetaxel for advanced non-small cell lung cancer", ANTI-CANC D, 12, 2001, pp. S11-S16
24. Barbounis, V; Koumakis, G; Vassilomanolakis, M; Demiri, M; Efremidis, AP
    Control of irinotecan-induced diarrhea by octreotide after loperamide failure
    SUPPORTIVE CARE IN CANCER
    
    V. Barbounis et al., "Control of irinotecan-induced diarrhea by octreotide after loperamide failure", SUPP CARE C, 9(4), 2001, pp. 258-260
25. Vermorken, JB; Zanetta, G; Oliveira, CFD; van der Burg, MEL; Lacave, AJ; Teodorovic, I; Boes, GH; Colombo, N
    Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma ofthe uterine cervix: An EORTC Gynecological Cancer Cooperative Group study
    ANNALS OF ONCOLOGY
    
    J.B. Vermorken et al., "Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma ofthe uterine cervix: An EORTC Gynecological Cancer Cooperative Group study", ANN ONCOL, 12(7), 2001, pp. 967-974
26. Alberts, SR; Erlichman, C; Sloan, J; Okuno, SH; Burch, PA; Rubin, J; Pitot, HC; Goldberg, RM; Adjei, AA; Atherton, PJ; Kaufmann, SH
    Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks
    ANNALS OF ONCOLOGY
    
    S.R. Alberts et al., "Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks", ANN ONCOL, 12(5), 2001, pp. 627-631
27. Scheithauer, W; Kornek, GV; Schuell, B; Ulrich-Pur, H; Penz, M; Raderer, M; Lang, F; Schneeweiss, B; Lenauer, A; Depisch, D
    Second-line treatment with oxaliplatin plus raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy
    ANNALS OF ONCOLOGY
    
    W. Scheithauer et al., "Second-line treatment with oxaliplatin plus raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy", ANN ONCOL, 12(5), 2001, pp. 709-714
28. Sanz-Altamira, PM; O'Reilly, E; Stuart, KE; Raeburn, L; Steger, C; Kemeny, NE; Saltz, LB
    A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma
    ANNALS OF ONCOLOGY
    
    P.M. Sanz-Altamira et al., "A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma", ANN ONCOL, 12(4), 2001, pp. 501-504
29. Volk, J; Reinke, F; van Kuilenburg, ABP; van Gennip, AH; Schlichting, C; Ganser, A; Schoffski, P
    Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer
    ANNALS OF ONCOLOGY
    
    J. Volk et al., "Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer", ANN ONCOL, 12(4), 2001, pp. 569-571
30. Grumett, SA; Archer, VR; Midgley, R; Mulholland, P; Nicum, S; Blewitt, L; Kerr, DJ
    The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy
    ANNALS OF ONCOLOGY
    
    S.A. Grumett et al., "The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy", ANN ONCOL, 12(4), 2001, pp. 575-575
31. Bonetti, A; Zaninelli, M; Leone, R; Franceschi, T; Fraccon, AP; Pasini, F; Sabbioni, R; Cetto, GL; Sich, D; Brienza, S; Howell, SB
    Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma
    ANNALS OF ONCOLOGY
    
    A. Bonetti et al., "Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma", ANN ONCOL, 12(2), 2001, pp. 187-191
32. Huisman, C; Postmus, PE; Giaccone, G; Smit, EF
    A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients
    ANNALS OF ONCOLOGY
    
    C. Huisman et al., "A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients", ANN ONCOL, 12(11), 2001, pp. 1567-1573
33. Blanke, CD; Haller, DG; Benson, AB; Rothenberg, ML; Berlin, J; Mori, M; Hsieh, YC; Miller, LL
    A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma
    ANNALS OF ONCOLOGY
    
    C.D. Blanke et al., "A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma", ANN ONCOL, 12(11), 2001, pp. 1575-1580
34. Rothenberg, ML; Kuhn, JG; Schaaf, LJ; Rodriguez, GI; Eckhardt, SG; Villalona-Calero, MA; Rinaldi, DA; Hammond, LA; Hodges, S; Sharma, A; Elfring, GL; Petit, RG; Locker, PK; Miller, LL; von Hoff, DD
    Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks
    ANNALS OF ONCOLOGY
    
    M.L. Rothenberg et al., "Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks", ANN ONCOL, 12(11), 2001, pp. 1631-1641
35. Oguma, T; Yamada, M; Konno, T; Inukai, K; Nakaoka, M
    High-performance liquid chromatographic analysis of lactone and hydroxy acid of new antitumor drug, DX-8951 (Exatecan), in mouse plasma
    BIOLOGICAL & PHARMACEUTICAL BULLETIN
    
    T. Oguma et al., "High-performance liquid chromatographic analysis of lactone and hydroxy acid of new antitumor drug, DX-8951 (Exatecan), in mouse plasma", BIOL PHAR B, 24(2), 2001, pp. 176-180
36. Sakai, C; Iuchi, T; Ishii, A; Kumagai, K; Takagi, T
    Bacillus cereus brain abscesses occurring in a severely neutropenic patient: Successful treatment with antimicrobial agents, granulocyte colony-stimulating factor and surgical drainage
    INTERNAL MEDICINE
    
    C. Sakai et al., "Bacillus cereus brain abscesses occurring in a severely neutropenic patient: Successful treatment with antimicrobial agents, granulocyte colony-stimulating factor and surgical drainage", INTERN MED, 40(7), 2001, pp. 654-657
37. Shimizu, M; Tamura, T; Yamada, Y; Akiyama, Y; Saijo, N; Nishio, K
    CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNAin mouse liver
    JAPANESE JOURNAL OF CANCER RESEARCH
    
    M. Shimizu et al., "CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNAin mouse liver", JPN J CANC, 92(5), 2001, pp. 554-561
38. Haller, DG
    Update on chemotherapy for advanced colorectal cancer
    ONCOLOGY-NEW YORK
    
    D.G. Haller, "Update on chemotherapy for advanced colorectal cancer", ONCOLOGY-NY, 15(3), 2001, pp. 11-15
39. Rich, TA; Kirichenko, AV
    Camptothecin schedule and timing of administration with irradiation
    ONCOLOGY-NEW YORK
    
    T.A. Rich e A.V. Kirichenko, "Camptothecin schedule and timing of administration with irradiation", ONCOLOGY-NY, 15(3), 2001, pp. 37-41
40. Beretta, GD; Pessi, MA; Poletti, P; Mosconi, S; Labianca, R
    New drugs and combinations in the palliative treatment of colon and rectalcancer
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY
    
    G.D. Beretta et al., "New drugs and combinations in the palliative treatment of colon and rectalcancer", EUR J SUR O, 27(6), 2001, pp. 595-600
41. Hoff, PM; Ansari, R; Batist, G; Cox, J; Kocha, W; Kuperminc, M; Maroun, J; Walde, D; Weaver, C; Harrison, E; Burger, HU; Osterwalder, B; Wang, AO; Wong, R
    Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
    JOURNAL OF CLINICAL ONCOLOGY
    
    P.M. Hoff et al., "Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study", J CL ONCOL, 19(8), 2001, pp. 2282-2292
42. Taamma, A; Misset, JL; Riofrio, M; Guzman, C; Brain, E; Lazaro, LL; Rosing, H; Jimeno, JM; Cvitkovic, E
    Phase I and pharmacokinetic study of ecteinaseidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors
    JOURNAL OF CLINICAL ONCOLOGY
    
    A. Taamma et al., "Phase I and pharmacokinetic study of ecteinaseidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors", J CL ONCOL, 19(5), 2001, pp. 1256-1265
43. Vanhoefer, U; Harstrick, A; Achterrath, W; Cao, SS; Seeber, S; Rustum, YM
    Irinotecan in the treatment of colorectal cancer: Clinical overview
    JOURNAL OF CLINICAL ONCOLOGY
    
    U. Vanhoefer et al., "Irinotecan in the treatment of colorectal cancer: Clinical overview", J CL ONCOL, 19(5), 2001, pp. 1501-1518
44. Van Cutsem, E; Twelves, C; Cassidy, J; Allman, D; Bajetta, E; Boyer, M; Bugat, R; Findlay, M; Frings, S; Jahn, M; McKendrick, J; Osterwalder, B; Perez-Manga, G; Rosso, R; Rougier, P; Schmiegel, WH; Seitz, JF; Thompson, P; Vieitez, JM; Weitzel, C; Harper, P
    Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
    JOURNAL OF CLINICAL ONCOLOGY
    
    E. Van Cutsem et al., "Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study", J CL ONCOL, 19(21), 2001, pp. 4097-4106
45. de Jongh, FE; Verweij, J; Loos, WJ; de Wit, R; de Jonge, MJA; Planting, AST; Nooter, K; Stoter, G; Sparreboom, A
    Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure
    JOURNAL OF CLINICAL ONCOLOGY
    
    F.E. de Jongh et al., "Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure", J CL ONCOL, 19(17), 2001, pp. 3733-3739
46. Arimori, K; Kuroki, N; Kumamoto, A; Tanoue, N; Nakano, M; Kumazawa, E; Tohgo, A; Kikuchi, M
    Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents
    PHARMACEUTICAL RESEARCH
    
    K. Arimori et al., "Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents", PHARM RES, 18(6), 2001, pp. 814-822
47. Nolte, W; Ramadori, G
    New aspects in the palliative treatment of metastatic colorectal carcinoma
    MEDIZINISCHE KLINIK
    
    W. Nolte e G. Ramadori, "New aspects in the palliative treatment of metastatic colorectal carcinoma", MED KLIN, 96(9), 2001, pp. 521-528
48. Reimer, P; Ruckle-Lanz, H
    New therapeutic options in the chemotherapy of advanced colorectal cancer
    MEDIZINISCHE KLINIK
    
    P. Reimer e H. Ruckle-Lanz, "New therapeutic options in the chemotherapy of advanced colorectal cancer", MED KLIN, 96(10), 2001, pp. 593-598
49. Louvet, C
    New chemotherapies for colorectal cancer treatment
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
    
    C. Louvet, "New chemotherapies for colorectal cancer treatment", GASTRO CL B, 25(4), 2001, pp. B51-B56
50. Azevedo, P; Verschraegen, CF; Kavanagh, JJ; Kudelka, AP; Freedman, RS; Lu, K; Deavers, MT
    Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
    
    P. Azevedo et al., "Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report", EUR J GYN O, 22(5), 2001, pp. 319-321
51. Honecker, F; Wedding, U; Kolb, G; Bokemeyer, C
    Chemotherapy in colorectal cancer - Which therapy is justified in elderly patients?
    ONKOLOGIE
    
    F. Honecker et al., "Chemotherapy in colorectal cancer - Which therapy is justified in elderly patients?", ONKOLOGIE, 24(1), 2001, pp. 87-94
52. Shigeoka, Y; Itoh, K; Igarashi, T; Ishizawa, K; Saeki, T; Fujii, H; Minami, H; Imoto, S; Sasaki, Y
    Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY
    
    Y. Shigeoka et al., "Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens", JPN J CLIN, 31(8), 2001, pp. 370-374
53. Crane, CH; Janjan, NA; Abbruzzese, JL; Curley, S; Vauthey, JN; Sawaf, HB; Dubrow, R; Allen, P; Ellis, LM; Hoff, P; Wolff, RA; Lenzi, R; Brown, TD; Lynch, P; Cleary, K; Rich, TA; Skibber, J
    Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    
    C.H. Crane et al., "Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer", INT J RAD O, 49(1), 2001, pp. 107-116
54. Sloan, JA; Atherton, P; Reid, J; Pilot, HC; Erlichman, C; Schaaf, L
    Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    J.A. Sloan et al., "Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide", CANC CHEMOT, 48(3), 2001, pp. 241-249
55. Cavazos, CM; Keir, ST; Yoshinari, T; Bigner, DD; Friedman, HS
    Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxy) ethylamino-12,13-dihydro-13-(beta-D-gluco pyranosyl)5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    C.M. Cavazos et al., "Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxy) ethylamino-12,13-dihydro-13-(beta-D-gluco pyranosyl)5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts", CANC CHEMOT, 48(3), 2001, pp. 250-254
56. Takeda, K; Negoro, S; Takifuji, N; Nitta, T; Yoshimura, N; Terakawa, K; Fukuoka, M
    Dose escalation study of irinotecan combined with carboplatin for advancednon-small-cell lung cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    K. Takeda et al., "Dose escalation study of irinotecan combined with carboplatin for advancednon-small-cell lung cancer", CANC CHEMOT, 48(2), 2001, pp. 104-108
57. Keir, ST; Hausheer, F; Lawless, AA; Bigner, DD; Friedman, HS
    Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    S.T. Keir et al., "Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice", CANC CHEMOT, 48(1), 2001, pp. 83-87
58. Sato, A; Kurihara, M; Matsukawa, M; Shimada, K; Yamazaki, T; Nakamachi, M; Koda, T
    Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    A. Sato et al., "Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer", CANC CHEMOT, 47(5), 2001, pp. 380-384
59. Guemei, AA; Cottrell, J; Band, R; Hehman, H; Prudhomme, M; Pavlov, MV; Grem, JL; Ismail, AS; Bowen, D; Taylor, RE; Takimoto, CH
    Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    A.A. Guemei et al., "Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan", CANC CHEMOT, 47(4), 2001, pp. 283-290
60. Thompson, J; Guichard, SM; Cheshire, PJ; Richmond, LB; Poquette, CA; Ragsdale, ST; Webber, B; Lorsbach, R; Danks, MK; Houghton, PJ
    Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    J. Thompson et al., "Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice", CANC CHEMOT, 47(3), 2001, pp. 211-221
61. Kobayashi, K; Ceryak, S; Matsuzaki, Y; Kudoh, S; Bouscarel, B
    Effect of bile acids on the uptake of irinotecan and its active metabolite, SN-38, by intestinal cells
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
    
    K. Kobayashi et al., "Effect of bile acids on the uptake of irinotecan and its active metabolite, SN-38, by intestinal cells", BBA-GEN SUB, 1525(1-2), 2001, pp. 125-129
62. Grifalchi, F; Padovani, A; Romeo, F; Trinca, C; Moscetti, L; Cortesi, E
    Response of metastatic epidermoid anal cancer to single agent irinotecan: A case report
    TUMORI
    
    F. Grifalchi et al., "Response of metastatic epidermoid anal cancer to single agent irinotecan: A case report", TUMORI, 87(1), 2001, pp. 58-59
63. Lokich, J
    Phase I clinical trial of weekly combined topotecan and irinotecan
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    
    J. Lokich, "Phase I clinical trial of weekly combined topotecan and irinotecan", AM J CL ONC, 24(4), 2001, pp. 336-340
64. Gil-Delgado, MA; Antoine, EC; Guinet, F; Bassot, V; Grapin, JP; Benhammonda, A; Adam, R; Castaing, D; Bismuth, H; Khayat, D
    Phase I-II study of irinotecan in combination with mitomycin C in patientswith advanced gastrointestinal cancer
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    
    M.A. Gil-Delgado et al., "Phase I-II study of irinotecan in combination with mitomycin C in patientswith advanced gastrointestinal cancer", AM J CL ONC, 24(3), 2001, pp. 251-254
65. Shields, AF; Lange, M; Zalupski, MM
    Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    
    A.F. Shields et al., "Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer", AM J CL ONC, 24(1), 2001, pp. 96-98
66. Gil-Delgado, MA; Guinet, F; Castaing, D; Adam, R; Coeffic, D; Durrani, AKS; Bismuth, H; Khayat, D
    Prospective phase II trial of irinotecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    
    M.A. Gil-Delgado et al., "Prospective phase II trial of irinotecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer", AM J CL ONC, 24(1), 2001, pp. 101-105
67. Topcu, Z
    DNA topoisomerases as targets for anticancer drugs
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    
    Z. Topcu, "DNA topoisomerases as targets for anticancer drugs", J CLIN PH T, 26(6), 2001, pp. 405-416
68. Hanioka, N; Jinno, H; Nishimura, T; Ando, M; Ozawa, S; Sawada, J
    High-performance liquid chromatographic assay for glucuronidation activityof 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes
    BIOMEDICAL CHROMATOGRAPHY
    
    N. Hanioka et al., "High-performance liquid chromatographic assay for glucuronidation activityof 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes", BIOMED CHRO, 15(5), 2001, pp. 328-333
69. Wang, XH; Fujimoto, T; Zhang, B; Mai, M
    Streptococcal preparation OK-432 enhances the antitumor activity of CPT-11by increasing Th1-cytokine production in mice
    ANTICANCER RESEARCH
    
    X.H. Wang et al., "Streptococcal preparation OK-432 enhances the antitumor activity of CPT-11by increasing Th1-cytokine production in mice", ANTICANC R, 21(4A), 2001, pp. 2505-2510
70. Vokes, EE; Gordon, GS; Rudin, CM; Mauer, AM; Watson, S; Krauss, S; Arrieta, R; Golomb, HM; Hoffman, PC
    A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer
    INVESTIGATIONAL NEW DRUGS
    
    E.E. Vokes et al., "A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer", INV NEW DR, 19(4), 2001, pp. 329-333
71. Pro, B; Lozano, R; Ajani, JA
    Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea
    INVESTIGATIONAL NEW DRUGS
    
    B. Pro et al., "Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea", INV NEW DR, 19(4), 2001, pp. 341-343
72. Miya, T; Goya, T; Fujii, H; Ohtsu, T; Itoh, K; Igarashi, T; Minami, H; Sasaki, Y
    Factors affecting the pharmacokinetics of CPT-11: The body mass index, ageand sex are independent predictors of pharmacokinetic parameters of CPT-11
    INVESTIGATIONAL NEW DRUGS
    
    T. Miya et al., "Factors affecting the pharmacokinetics of CPT-11: The body mass index, ageand sex are independent predictors of pharmacokinetic parameters of CPT-11", INV NEW DR, 19(1), 2001, pp. 61-67
73. Turker, L
    A theoretical study on camptothecin-AM1 treatment
    JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM
    
    L. Turker, "A theoretical study on camptothecin-AM1 treatment", J MOL ST-TH, 549(3), 2001, pp. 275-283
74. Grivicich, I; Mans, DRA; Peters, GJ; Schwartsmann, G
    Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
    
    I. Grivicich et al., "Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer", BRAZ J MED, 34(9), 2001, pp. 1087-1103
75. Prados, M
    Temozolomide in combination with other cytotoxic agents
    SEMINARS IN ONCOLOGY
    
    M. Prados, "Temozolomide in combination with other cytotoxic agents", SEMIN ONCOL, 28(4), 2001, pp. 24-33
76. O'Connell, MJ
    North Central Cancer Treatment Group-Mayo Clinic trials in colon cancer
    SEMINARS IN ONCOLOGY
    
    M.J. O'Connell, "North Central Cancer Treatment Group-Mayo Clinic trials in colon cancer", SEMIN ONCOL, 28(1), 2001, pp. 4-8
77. Sai, K; Kaniwa, N; Ozawa, S; Sawada, JI
    A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4
    DRUG METABOLISM AND DISPOSITION
    
    K. Sai et al., "A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4", DRUG META D, 29(11), 2001, pp. 1505-1513
78. Hanioka, N; Ozawa, S; Jinno, H; Ando, M; Saito, Y; Sawada, J
    Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin
    XENOBIOTICA
    
    N. Hanioka et al., "Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin", XENOBIOTICA, 31(10), 2001, pp. 687-699
79. Comella, P; Biglietto, M; Casaretti, R; De Luica, L; Avallone, A; Maiorino, L; Di Lullo, L; De Cataldis, G; Rivellini, F; Comella, G
    Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients - A phase I/II study of the Southern Italy Cooperative Oncology Group
    ONCOLOGY
    
    P. Comella et al., "Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients - A phase I/II study of the Southern Italy Cooperative Oncology Group", ONCOL-BASEL, 60(2), 2001, pp. 127-133
80. Wadkins, RM; Morton, CL; Weeks, JK; Oliver, L; Wierdl, M; Danks, MK; Potter, PM
    Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases
    MOLECULAR PHARMACOLOGY
    
    R.M. Wadkins et al., "Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases", MOLEC PHARM, 60(2), 2001, pp. 355-362
81. Farabos, C; Haaz, MC; Gires, P; Robert, J
    Hepatic extraction, metabolism, and biliary excretion of irinotecan in theisolated perfused rat liver
    JOURNAL OF PHARMACEUTICAL SCIENCES
    
    C. Farabos et al., "Hepatic extraction, metabolism, and biliary excretion of irinotecan in theisolated perfused rat liver", J PHARM SCI, 90(6), 2001, pp. 722-731
82. Takeda, Y; Kobayashi, K; Akiyama, Y; Soma, T; Handa, S; Kudoh, S; Kudo, K
    Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients
    INTERNATIONAL JOURNAL OF CANCER
    
    Y. Takeda et al., "Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients", INT J CANC, 92(2), 2001, pp. 269-275
83. Fujita, A; Takabatake, H; Tagaki, S; Sekine, K
    Combination chemotherapy in patients with malignant pleural effusions fromnon-small cell lung cancer - Cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony-stimulating factor support
    CHEST
    
    A. Fujita et al., "Combination chemotherapy in patients with malignant pleural effusions fromnon-small cell lung cancer - Cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony-stimulating factor support", CHEST, 119(2), 2001, pp. 340-343
84. Iyengar, RV; Pawlik, CA; Krull, EJ; Phelps, DA; Burger, RA; Harris, LC; Potter, PM; Danks, MK
    Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression
    CANCER RESEARCH
    
    R.V. Iyengar et al., "Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression", CANCER RES, 61(7), 2001, pp. 3045-3052
85. Boushey, RP; Yusta, B; Drucker, DJ
    Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor
    CANCER RESEARCH
    
    R.P. Boushey et al., "Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor", CANCER RES, 61(2), 2001, pp. 687-693
86. Wierdl, M; Morton, CL; Weeks, JK; Danks, MK; Harris, LC; Potter, PM
    Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase
    CANCER RESEARCH
    
    M. Wierdl et al., "Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase", CANCER RES, 61(13), 2001, pp. 5078-5082
87. Meck, MM; Wierdl, M; Wagner, LM; Burger, RA; Guichard, SM; Krull, EJ; Harris, LC; Potter, PM; Danks, MK
    A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11
    CANCER RESEARCH
    
    M.M. Meck et al., "A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11", CANCER RES, 61(13), 2001, pp. 5083-5089
88. Firvida, JL; Irigoyen, A; Vazquez-Estevez, S; Diz, P; Constenla, M; Casal-Rubio, J; Valladares-Ayerbes, M; Castellanos, J; Rodriguez, R; Balcells, M
    Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma
    CANCER
    
    J.L. Firvida et al., "Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma", CANCER, 91(4), 2001, pp. 704-711
89. Garufi, G; Dogliotti, L; D'Attino, RM; Tampellini, M; Aschelter, AM; Pugliese, P; Perrone, M; Nistico, C; Comis, S; Terzoli, E
    Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acidin the treatment of patients with advanced colorectal carcinoma - A phase I study
    CANCER
    
    G. Garufi et al., "Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acidin the treatment of patients with advanced colorectal carcinoma - A phase I study", CANCER, 91(4), 2001, pp. 712-720
90. O'Reilly, EM; Stuart, KE; Sanz-Altamira, PM; Schwartz, GK; Steger, CM; Raeburn, L; Kemeny, NE; Kelsen, DP; Saltz, LB
    A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma
    CANCER CYTOPATHOLOGY
    
    E.M. O'Reilly et al., "A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma", CANC CYTOP, 91(1), 2001, pp. 101-105
91. O'Reilly, EM; Stuart, KE; Sanz-Altamira, PM; Schwartz, GK; Steger, CM; Raeburn, L; Kemeny, NE; Kelsen, DP; Saltz, LB
    A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma
    CANCER
    
    E.M. O'Reilly et al., "A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma", CANCER, 91(1), 2001, pp. 101-105
92. Ducreux, N; Fizazi, K; Seitz, JF; Becouarn, Y; Armand, JP
    Oxaliplatin in combination with non fluoropyrimidine drugs in colorectal cancer
    BULLETIN DU CANCER
    
    N. Ducreux et al., "Oxaliplatin in combination with non fluoropyrimidine drugs in colorectal cancer", B CANCER, 88, 2001, pp. S35-S39
93. Dodds, HM; Rivory, LP
    Comment on a published paper
    BRITISH JOURNAL OF PHARMACOLOGY
    
    H.M. Dodds e L.P. Rivory, "Comment on a published paper", BR J PHARM, 134(2), 2001, pp. 448-449
94. Blandizzi, C; De Paolis, B; Colucci, R; Lazzeri, G; Baschiera, F; Del Tacca, M
    Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan
    BRITISH JOURNAL OF PHARMACOLOGY
    
    C. Blandizzi et al., "Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan", BR J PHARM, 132(1), 2001, pp. 73-84
95. Chau, I; Webb, A; Cunningham, D; Hill, M; Waters, JS; Norman, A; Massey, A
    Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer
    BRITISH JOURNAL OF CANCER
    
    I. Chau et al., "Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer", BR J CANC, 85(9), 2001, pp. 1258-1264
96. Cyjon, A; Neuman-Levin, M; Rakowsky, E; Greif, F; Belinky, A; Atar, E; Hardoff, R; Brenner, B; Sulkes, A
    Liver metastases from colorectal cancer: regional intra-arterial treatmentfollowing failure of systemic chemotherapy
    BRITISH JOURNAL OF CANCER
    
    A. Cyjon et al., "Liver metastases from colorectal cancer: regional intra-arterial treatmentfollowing failure of systemic chemotherapy", BR J CANC, 85(4), 2001, pp. 504-508
97. Bensmaine, MA; Marty, M; de Gramont, A; Brienza, S; Levi, F; Ducreux, M; Francois, E; Gamelin, E; Bleiberg, H; Cvitkovic, E
    Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
    BRITISH JOURNAL OF CANCER
    
    M.A. Bensmaine et al., "Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients", BR J CANC, 85(4), 2001, pp. 509-517
98. Ueoka, H; Tanimoto, M; Kiura, K; Tabata, M; Takigawa, N; Segawa, Y; Takata, I; Eguchi, K; Okimoto, N; Harita, S; Kamei, H; Shibayama, T; Watanabe, Y; Hiraki, S; Harada, M
    Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group
    BRITISH JOURNAL OF CANCER
    
    H. Ueoka et al., "Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group", BR J CANC, 85(1), 2001, pp. 9-13
99. Sobrero, A; Guglielmi, A; Cirillo, M; Recaldin, E; Frassineti, GL; Aschele, C; Ravaioli, A; Testore, P; Caroti, C; Gallo, L; Pessi, MA; Cortesi, E; Turci, D; Grossi, F; Labianca, R
    5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highlyeffective, low cost chemotherapy for advanced colorectal cancer
    BRITISH JOURNAL OF CANCER
    
    A. Sobrero et al., "5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highlyeffective, low cost chemotherapy for advanced colorectal cancer", BR J CANC, 84(8), 2001, pp. 1023-1028
100. Fischel, JL; Rostagno, P; Formento, P; Dubreuil, A; Etienne, MC; Milano, G
     Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines
     BRITISH JOURNAL OF CANCER
     
     J.L. Fischel et al., "Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines", BR J CANC, 84(4), 2001, pp. 579-585